Kornimate/medical-research-clean huggingface dataset:
effect and mechanism of dopamine on ulcerative colitis

Conditions: Dopamine Dysregulation Syndrome; Ulcerative Colitis

Summary: increased evidence suggests that dopamine acts as an important regulator of immune function. a substantial amount of dopamine exists in the gastrointestinal tract, especially in colonic lumen. decreased dopamine level has been reported in the colonic mucosa of ulcerative colitis patients. therefore, the investigators suppose that colonic dopamine could involve in the ulcerative colitis and play an important role. this study aims to explore the role of dopamine in ulcerative colitis and underlying mechanism, which will provide a rationale for diagnosis and treatment of the ulcerative colitis.

this study is a case-control clinical study. 30 patients with non-ulcerative colitis examined by endoscopy were selected as the control group. according to the inclusion and exclusion criteria, 30 patients with ulcerative colitis were determined. the baseline data of patients were recorded objectively: name, sex, age, vital signs, body weight and stool condition (frequency, character, etc.). some laboratory examination results (blood routine, fecal routine and fecal culture, liver function, blood coagulation function, electrolyte, etc.), ulcerative colitis lesion range, ulcerative colitis classification and related history (common disease, treatment history and life history). colonic mucosal tissue samples of patients with ulcerative colitis and control group were obtained by colonoscopic biopsy. the degree of inflammation was evaluated by related inflammatory factors via elisa. the changes of dopamine system was detected by hplc-ecd, western blot and immunohistochemistry. this study aims to provide new diagnostic and therapeutic basis, select appropriate drug delivery through clarify the effect and mechanism of local dopamine on colitis.

Eligibility criteria:
inclusion criteria: 1. patients with or without ulcerative colitis diagnosed by endoscopy and histopathology 2. negative bacterial culture in stool 3. written informed consent exclusion criteria: 1. patients with cardiovascular and cerebrovascular diseases, or patients with severe impairment of liver, kidney and hematopoietic system 2. mental patients 3. hemorrhagic diseases 4. platelet count \< 50 × 10 \^ 9 / l 5. allergic constitution 6. unable to tolerate or cooperate with endoscopy 7. patients with serious complications, such as intestinal obstruction, intestinal perforation, toxic colonic dilatation, colorectal cancer, etc. 8. pregnant or lactating women

Keywords: dopamine ulcerative colitis
lifestyle intervention program for cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the purpose of the lifestyle intervention study is to investigate the influence of a micronutrient supplement in combination with a comprehensive lifestyle intervention program on retinal amyloid, among patients with mild cognitive impairment (mci). patients will be placed on supplement or placebo throughout their 18-month study participation. patients will also be given lifestyle training on nutrition, physical activity, cognitive and social activity, meditation and sleep, which have all been proven to positively affect cognition over time. throughout their participation, patients' cognitive functioning will be monitored with comprehensive imaging, neuropsychological testing, blood testing and study compliance.


Eligibility criteria:
inclusion criteria: * age ≥ 55 years of age * experiencing memory, or cognitive problems exclusion criteria: * patients \< 55 years of age * previously diagnosed dementia; suspected dementia after clinical assessment by study physician at screening visit * mini mental state examination (mmse) score less than 20 points * disorders affecting safe engagement in the intervention (e.g., malignant disease, major depression, psychiatric disease, symptomatic cardiovascular disease, revascularization within 1 year previously) * unable to safely change diet * patients without the means to visit the clinic on the assigned dates * patients that cannot comply with the data gathering needs of the study * severe loss of vision, hearing, or communicative ability * disorders preventing cooperation as judged by the study physician * coincident participation in another intervention trial * allergy to any ingredient in the supplement or placebo (i.e. soybean oil) * patients with gallstones due to possible interactions with turmeric * participants who are unable to provide clearance from their physician to participate in the physical activity training, as well as confirmed by dr. sherzai during the neurological exam.

Keywords: memory
osteoporosis and colles fracture

Conditions: Previous or Actual Colles Fracture

Summary: the primary purpose of the retrospective study is to determine the incidence of osteoporosis in women with previous colles fracture. secondly, to determine to which extent colles fracture has led to a diagnosis and/or treatment of osteoporosis. the primary purpose of the prospective study is to determine the incidence of osteoporosis in women with an actual colles fracture. secondly, to investigate the consistency between prospective and retrospective data.

colles fracture is known to be connected to decreased bone mineral density (bmd). thus, it can be an early sign of osteoporosis and therefore an increased risk of new fractures. the results of earlier studies have not been unambiguous in the respect of what extent decreased bmd in the wrist of women with colles fracture is synonymous of osteoporosis in the spine and the hip. an earlier enquiry to the danish orthopedic departments in 1995 showed that only 18 % of the departments diagnosed or referred patients with possible osteoporosis. the two study designs enhance the possibilities of evaluating the relevance of low energy fractures in the wrist to avoid new fractures and their relation to bone mineral density. the results could also be a useful tool in quality assurance of the osteoporosis diagnostics.

Eligibility criteria:
inclusion criteria: colles fracture women over 40 years informed consent- exclusion criteria: high energy fracture deceases or conditions that makes the participant unable to contribute to the investigation-

Keywords: colles fracture osteoporosis bmd quality assurance
randomized study of decreased hyperinsulinemia on the ovulatory response to clomiphene citrate in women with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Hyperinsulinism

Summary: objectives: i. determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene citrate in women with polycystic ovary syndrome.

protocol outline: this is a randomized, double blind, placebo controlled, multicenter study. patients are randomized to one of two treatment arms. patients receive oral metformin or oral placebo three times daily for 7 weeks. patients remaining anovulatory by day 49 receive metformin or placebo plus escalating doses of oral clomiphene citrate daily for 5 consecutive days, beginning on days 50, 80, and 110. following ovulation, treatment with clomiphene citrate and metformin or placebo continues until 6 ovulatory cycles occur, pregnancy occurs, or anovulation persists. patients receiving the placebo arm who have not ovulated on the highest dose of clomiphene citrate may be crossed over to receive metformin after a 6 week washout.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- patients with chronic anovulation due to polycystic ovary syndrome (pcos) who have failed clomiphene citrate must have oligoovulation and hyperandrogenemia --prior/concurrent therapy-- endocrine therapy: at least 2 months since prior clomiphene citrate other: * at least 2 months since prior standard therapy (including over the counter drugs) * at least 2 months since prior investigational drugs * prior multi/prenatal vitamins allowed --patient characteristics-- hematopoietic: hematocrit greater than 38% hepatic: * liver function normal * no clinically significant hepatic disease renal: * no clinically significant renal disease * creatinine less than 1.4 mg/dl * no proteinuria cardiovascular: no clinically significant cardiac disease pulmonary: no clinically significant pulmonary disease hormonal: * thyroid function normal * prolactin normal * estradiol normal * fasting 17 alpha-hydroxy progesterone less than 200 ng/dl or no late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency other: * not pregnant * negative pregnancy test * male partner must have a normal semen analysis by who criteria * must be in acceptable health by interview, medical history, physical exam, and laboratory tests * no diabetes mellitus * no clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease * no clinically significant malignant disease except nonmelanomatous skin cancer * at least 1 year since any prior drug abuse or alcoholism

Keywords: endocrine disorders hyperinsulinism polycystic ovarian syndrome rare disease
endothelialized eptfe graft by nanobiotechnology

Conditions: The Apparatus for Processing the Tubular Graft Modification Will be Designed and Evaluated.; The On-site Capturing of the Endothelial (Progenitor) Cells by Peptide-mediated Selective Adhesion in Vitro and in Vivo Will Also be Elucidated.; The Patency Rate of ITRI-made Artificial Blood Vessels Will be Evaluated by the Porcine Animal Model.

Summary: the replacement of autologous blood vessels by artificial grafts is urgently needed in clinical applications. expanded polytetrafluoroethylene (eptfe) grafts are the most clinically used artificial blood vessels because of its chemical and mechanical stability. but, when used as arteriovenous (av) grafts for haemodialysis, small diameter eptfe grafts have a high failure rate of 40% in three years in vivo because of the functional lack of an intact endothelial cell layer. here we developed a two-step modification including chemical etching and plasma activation to enhance the hydrophilicity of eptfe. peptide motifs (eg. cyclic rre, rgd) known to bind integrins on the endothelial cells were immobilized on eptfe grafts. functional peptide immobilization significantly increased the adherence and growth of huvec cells on eptfes. patch eptfe implantation in the pig's descending aorta was used to evaluate the in vivo endothelialization of these modified eptfe grafts. at 28 days implantation, newly formed endothelial layers on peptide-immobilized eptfe grafts were demonstrated by sem and histological analysis. these preliminary data showed the potential to grow an intact endothelial layer to improve the patency rate of the modified eptfe grafts.


Eligibility criteria:
obtained from the peripheral blood leukocyte thick liquid (hsinchu blood center, taiwan blood services fundation) times - sampled 20 \~ 40ml / time, 2 to 3 times / month

Keywords: expanded polytetrafluoroethylene( eptfe)
effectiveness of hydrolyzed collagen peptide injection for the treatment of collateral ligament pain

Conditions: Collateral Ligament Injury of Stifle Joint

Summary: conducted by binh luu thi, lan tran thi, and minh hang hoang thi at thai nguyen national hospital, the study investigates a new approach to treating persistent collateral ligament pain, common among athletes. the research examines the therapeutic use of hydrolyzed collagen peptide injections, a treatment that addresses pain and inflammation in ways previous methods have not. the study involves a randomized controlled trial with 62 patients, all diagnosed with inflammation in the collateral ligament site. the patients are split into two groups: one receiving collagen injections alongside oral painkillers and the other receiving depo-medrol injections with oral painkillers.


Eligibility criteria:
inclusion criteria: * age above 18 years, * lateral knee pain with a duration of 3 months or longer, * ultrasound evidence of inflammation of the femoral condyle attachment point, * agreement to participate in the study exclusion criteria: * trauma, * infection, * dermatitis at the site of the inflammation, * damage to surrounding knee structures, * history of chronic inflammatory arthritis (such as gout or rheumatoid arthritis), * local corticosteroid injection within 3 months before participating in the study.

Keywords: collateral ligament pain knee pain knee instability sports trauma collagen peptide injections ligament healing
clinical trial evaluating the efficacy and safety of technosphere® inhalation insulin (ti) inhalation powder using the gen2 inhaler

Conditions: Type 2 Diabetes

Summary: this is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of technosphere insulin (ti) inhalation powder in combination with insulin glargine versus insulin aspart in combination with insulin glargine in subjects with type 2 diabetes.

phase 3 clinical trial is designed to examine the efficacy and safety of inhaled prandial ti inhalation powder in combination with basal insulin verses insulin aspart in combination with basal insulin in subjects with type 2 diabetes who are suboptimally controlled with their current insulin regimens.this trial will employ a variety of methods to intensively manage these subjects.

Eligibility criteria:
inclusion criteria: * men and women ≥ 18 and ≤ 80 years of age * clinical diagnosis of type 2 diabetes mellitus for more than 12 months * body mass index (bmi) ≤ 45 kg/m2 * glycated hemoglobin (hba1c) \> 6.5% and ≤ 10.0% * treatment with 1 to 3 oral antidiabetic drugs (oads) and basal insulin for a minimum of 3 months before screening. doses of oads must have been stable for 3 months before study entry * nonsmokers (includes cigarettes, cigars, pipes, and chewing tobacco) for the preceding ≥ 6 months * office spirometry at the investigator site * forced expiratory volume in 1 second (fev1) ≥ 65% third national health and nutrition examination survey (nhanes iii) predicted * forced vital capacity (fvc) ≥ 65% nhanes iii predicted * forced expiratory volume in 1 second as a percentage of forced vital capacity (fev1/fvc) ≥ lower limit of normal (lln) exclusion criteria: * current or prior treatment with prandial or premix (70/30) insulin * history of insulin pump use within 6 weeks of visit 1 * treatment with glucagon-like peptide (glp-1) analog drugs within the preceding 12 weeks of visit 1 * history of chronic obstructive pulmonary disease (copd), asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis) * any clinically significant radiological findings on screening chest x-ray * use of medications for asthma, copd, or any other chronic respiratory conditions * evidence of serious complications of diabetes (eg, symptomatic autonomic neuropathy) * significant cardiovascular dysfunction or history within 3 months of visit 1 (eg, congestive heart failure \[new york heart association {nyha} class iii or iv\]) * serious arrhythmia, myocardial infarction, cardiac surgery, recurrent syncope, transient ischemic attacks, or any cerebrovascular accident * history of pulmonary embolism or deep venous thrombosis in the 12 months before screening (visit 1)
comprehensive risk assessment of people with silicosis: a population-based study

Conditions: Silicosis

Summary: objectives: this study aims to explore the risk profiles among people with silicosis in hong kong underpinned by the pittsburgh mind-body center model. design and subjects: this study will adopt a cross-sectional study design with sampling stratified by participants' degree of incapability. 320 chinese people diagnosed with silicosis and registered with the pneumoconiosis compensation fund board will be recruited. data collection: a demographic data sheet and the st. george's respiratory questionnaire will be used to collect the socio-demographic and clinical characteristics of the participants. the behavioral factors (smoking, drinking, physical activity level, consumption of vegetable and fruits and plasma vitamin c level) as well as the psychological risk factors (anxiety and depressive symptoms, and social support) will be examined by validated questionnaires. biological and physiological parameters, including insulin resistance, c-reactive protein, hemoglobin, fasting blood glucose and lipid profiles, will be ascertained by fasting blood sample. data analysis and expected outcomes: the findings of this study will create the database profile of the physical, psychosocial and disease specific aspects among people with silicosis in hong kong, subsequently forming the empirical basis of an intervention to tackle the identified modifiable risks among them.


Eligibility criteria:
inclusion criteria: * hong kong chinese-speaking residents and chinese ethnicity; * diagnosis of silicosis and confirmed by the pneumoconiosis medical board * registered with the pneumoconiosis compensation fund board (pcfb); and * able and willing to give informed written consent exclusion criteria: * with medically diagnosed mental illness, including major depression, or * with active pulmonary tuberculosis
insulin sensitivity of the human cns system: fmri study with intranasal insulin application

Conditions: Obesity; Diabetes

Summary: the purpose of the study is to investigate whether insulin sensitivity and insulin resistance of the human brain is comparable in all insulin sensitive parts of the brain and whether correlates to other phenotypic information (i.e. whole body insulin sensitivity, bmi, age) of the study participants.


Eligibility criteria:
inclusion criteria: * normal routine blood works * for women: negative pregnancy test * healthy exclusion criteria: * type 2 diabetes * pregnancy * acute or chronic diseases * pacemakers * artificial heart valves * metal prostheses * implanted magnetic metal parts (screws, ...) * metal fragments * braces * insulin pumps * tattoos * claustrophobia * reduced temperature sensation and / or increased sensitivity to warming of the body * ear disease or an increased sensitivity to loud noises
the effects of the water-exchanged colonoscopy on adenoma detection rate

Conditions: Adenoma; Pain

Summary: water exchange method has been shown to reduce medication requirement and pain experienced during colonoscopy. it may increase the adenoma detection rate (adr). water exchange provides salvage cleansing and the refractive index of water (n equals about 1.3) is larger than that of air, which creates optical distortion that likely contributes to objects appearing larger underwater, making smaller lesions easier to visualize and it may help draw attention to those smaller lesions during withdraw. these principles facilitate to the higher adenoma detection rate. there is a large number of literature on the adenoma detection rate during water exchange colonoscopy, but most studies have been conducted in only one centre, simple-size, and under sedation patients, the influence of adenoma detection rate under unsedation patients was unclear. the aim of this study is to compare the adr of colonoscopy by using the water exchange method versus the conventional air method in unsedation patients in multiple centers in china.


Eligibility criteria:
inclusion criteria: * age 18-80 patients with intact colon and rectum exclusion criteria: * prior finding of severe colorectal stricture; * solid fetus contained in the last stool before colonoscopy * no bowel preparation or cleansed by enema/lavage * without the requirement of reaching cecum * known colorectal polyps or polyposis syndrome without complete removal previously * pregnant women * hemodynamically unstable * patients who cannot give informed consent

Keywords: colonoscopy water adenoma pain
sitagliptin/metformin fed bioequivalence study (0431a-080)

Conditions: Type 2 Diabetes Mellitus

Summary: this study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (fdc) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal.


Eligibility criteria:
inclusion criteria: * is in good health * is a nonsmoker * is willing to follow all study guidelines exclusion criteria: * has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant * is a nursing mother * is unwilling to consume the required high-fat breakfast
car t cells real world evidence study based on the french hospital claims data source (pmsi)

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL); Acute Lymphoblastic Leukemia (ALL)

Summary: this was a retrospective cohort study based on the pmsi data source

a retrospective database analysis was performed using the french national hospital claims database (medicalized information system program - pmsi, 2015-2019), which includes discharge summaries for all hospital admissions in france (\~99% of french residents). the patients were identified based on the car-t administration hospital stay, between 2017 and 2019. based on the exhaustivity of the database, all patients treated with car-t (since 2018) were identified. the study design included multiple periods of analysis based on the car-t process. three main periods were defined: the historical period, the car-t period, and the post car-t period. the car-t period was divided in 2 sub-periods: pre car-t (including the apheresis procedure and 15 days before this procedure) and per car-t (including the lymphodepletion and car-t cell injection hospital stay until the end at the discharge date related to car-t cell injection hospital stay). the follow-up period started at the end of car-t hospital stay. car-t populations: kymriah® dlbcl cohort: * adult patients (≥18 years of age) with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy. * patient with a car-t administration hospital stay of kymriah between 2017 and 2019 yescarta®dlbcl cohort: * adult patients (≥18 years of age) with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy: * patient with a car-t administration hospital stay of yescarta between 2017 and 2019 kymriah® all cohort: * pediatric and young adult patients (≤ 25 years of age) with b-cell acute lymphoblastic leukemia (all) that is refractory, in relapse post-transplant or in second or later relapse: * patient with a car-t administration hospital stay of kymriah between 2017 and 2019

Eligibility criteria:
inclusion criteria: * patients treated with car-t cells from 2017 to 2019 and informed as such in the pmsi and * patients diagnosed with all or dlbcl when administering car-t cells and * up to 25 years for patients with all exclusion criteria: * all patients treated outside the two types of indications presented in the inclusion criteria will be excluded